{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:27:32Z","timestamp":1792783652623,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"EU FP7 SILVER"},{"name":"BELSPO IUAP Consortium BELVIR"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.antiviral.2015.06.017","type":"journal-article","created":{"date-parts":[[2015,6,25]],"date-time":"2015-06-25T15:09:17Z","timestamp":1435244957000},"page":"59-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"special_numbering":"C","title":["Towards antivirals against chikungunya virus"],"prefix":"10.1016","volume":"121","author":[{"given":"Rana","family":"Abdelnabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0033-7514","authenticated-orcid":false,"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Delang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2015.06.017_b0005","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.berh.2011.03.005","article-title":"Arthritis after infection with chikungunya virus","volume":"25","author":"Ali","year":"2011","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.antiviral.2015.06.017_b0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2013.01.002","article-title":"Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus","volume":"98","author":"Bassetto","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.017_b0015","doi-asserted-by":"crossref","first-page":"e11479","DOI":"10.1371\/journal.pone.0011479","article-title":"Endocytosis of chikungunya virus into mammalian cells: role of clathrin and early endosomal compartments","volume":"5","author":"Bernard","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2015.06.017_b9000","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: anupdate","volume":"107","author":"Blaising","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.017_b0020","first-page":"87","article-title":"Chikungunya virus isolates with\/without A226V mutation show different sensitivity to IFN-alpha, but similar replication kinetics in non human primate cells","volume":"34","author":"Bordi","year":"2011","journal-title":"New Microbiol."},{"key":"10.1016\/j.antiviral.2015.06.017_b0025","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1021\/np300637t","article-title":"Prostratin and 12-O-tetradecanoylphorbol 13-acetate are potent and selective inhibitors of chikungunya virus replication","volume":"75","author":"Bourjot","year":"2012","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.antiviral.2015.06.017_b0030","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.3390\/molecules19033617","article-title":"Trigocherrierin a, a potent inhibitor of chikungunya virus replication","volume":"19","author":"Bourjot","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.antiviral.2015.06.017_b0035","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.antiviral.2003.09.005","article-title":"In vitro inhibition of chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-\u03b1 and ribavirin combination","volume":"61","author":"Briolant","year":"2004","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.017_b0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1371\/journal.pntd.0002790","article-title":"Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational rift valley fever","volume":"8","author":"Caroline","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.antiviral.2015.06.017_b0050","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.38221","article-title":"Effectiveness of chloroquine and inflammatory cytokine response in patients with early persistent musculoskeletal pain and arthritis following chikungunya virus infection","volume":"66","author":"Chopra","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.antiviral.2015.06.017_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002471","article-title":"Identification of novel compounds inhibiting chikungunya virus-induced cell death by high throughput screening of a kinase inhibitor library","volume":"7","author":"Cruz","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.antiviral.2015.06.017_b0060","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.bbrc.2008.09.040","article-title":"RNA interference mediated inhibition of chikungunya virus replication in mammalian cells","volume":"376","author":"Dash","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2015.06.017_b0065","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1093\/jac\/dku209","article-title":"Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral","volume":"69","author":"Delang","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2015.06.017_b0070","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.antiviral.2011.03.182","article-title":"In vitro antiviral activity of arbidol against chikungunya virus and characteristics of a selected resistant mutant","volume":"90","author":"Delogu","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.017_b0075","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.1016\/j.bmc.2014.09.013","article-title":"Structure-activity relationship study of arbidol derivatives as inhibitors of chikungunya virus replication","volume":"22","author":"Di Mola","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.antiviral.2015.06.017_b0080","first-page":"1065","volume":"21","author":"Falzarano","year":"2015","journal-title":"Chloroquine in mice and hamsters"},{"key":"10.1016\/j.antiviral.2015.06.017_b0085","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/infdis\/jis674","article-title":"Use of human monoclonal antibodies to treat chikungunya virus infection","volume":"207","author":"Fric","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.06.017_b0090","doi-asserted-by":"crossref","first-page":"10394","DOI":"10.1128\/JVI.00884-13","article-title":"The C-terminal domain of chikungunya virus nsP2 independently governs viral RNA replication, cytopathicity, and inhibition of interferon signaling","volume":"87","author":"Fros","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.06.017_b0095","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.017_b0100","unstructured":"Gigante, A., Canela, M., Delang, L., Priego, E., Camarasa, M., Querat, G., Neyts, J., Leyssen, P., 2014. No Title 7."},{"key":"10.1016\/j.antiviral.2015.06.017_b0105","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.clim.2013.10.004","article-title":"Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model","volume":"149","author":"Goh","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.antiviral.2015.06.017_b0110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.antiviral.2009.07.007","article-title":"Understanding the alphaviruses: recent research on important emerging pathogens and progress towards their control","volume":"87","author":"Gould","year":"2010","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.017_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002614","article-title":"Favipiravir (T-705) inhibits Jun\u00edn virus infection and reduces mortality in a guinea pig model of argentine hemorrhagic fever","volume":"7","author":"Gowen","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.antiviral.2015.06.017_b0120","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/md12010115","article-title":"Anti-chikungunya viral activities of aplysiatoxin-related compounds from the marine cyanobacterium Trichodesmium erythraeum","volume":"12","author":"Gupta","year":"2014","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.antiviral.2015.06.017_b0125","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1126\/science.1132505","article-title":"5\u2032-Triphosphate RNA is the ligand for RIG-I","volume":"314","author":"Hornung","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2015.06.017_b0130","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.antiviral.2015.03.013","article-title":"Benzouracil\u2013coumarin\u2013arene conjugates as inhibiting agents for chikungunya virus","volume":"118","author":"Hwu","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.017_b0135","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejmech.2014.10.042","article-title":"Thiazolidone derivatives as inhibitors of chikungunya virus","volume":"89","author":"Jadav","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.antiviral.2015.06.017_b0140","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.drudis.2013.05.002","article-title":"Chikungunya virus: an update on antiviral development and challenges","volume":"18","author":"Kaur","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.antiviral.2015.06.017_b0145","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1128\/AAC.01467-12","article-title":"Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression","volume":"57","author":"Kaur","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.06.017_b0150","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/jmv.21663","article-title":"Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against chikungunya virus in Vero cells","volume":"82","author":"Khan","year":"2010","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2015.06.017_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2010.10.009","article-title":"Cellular IMPDH enzyme activity is a potential target for the inhibition of chikungunya virus replication and virus induced apoptosis in cultured mammalian cells","volume":"89","author":"Khan","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.017_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2012.01.009","article-title":"Chikungunya fever","author":"Kucharz","year":"2012","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.antiviral.2015.06.017_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046396","article-title":"Expression of plasmid-based shRNA against the E1 and nsP1 genes effectively silenced chikungunya virus replication","volume":"7","author":"Lam","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2015.06.017_b0170","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1124\/mol.105.020057","article-title":"The anti-yellow fever virus activity of ribavirin is independent of error-prone replication","volume":"69","author":"Leyssen","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.antiviral.2015.06.017_b0175","article-title":"Poly (I:C), an agonist of toll-like receptor-3, inhibits replication of the chikungunya virus in BEAS-2B cells","author":"Li","year":"2012","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2015.06.017_b0180","article-title":"A phenotypic assay to identify chikungunya virus inhibitors targeting the nonstructural protein nsP2","author":"Lucas-Hourani","year":"2012","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.antiviral.2015.06.017_b0185","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.virol.2014.05.038","article-title":"Monoclonal antibody targeting chikungunya virus envelope 1 protein inhibits virus release","volume":"464\u2013465","author":"Masrinoul","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2015.06.017_b0190","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/805347","article-title":"Protein kinase C: One pathway towards the eradication of latent HIV-1 Reservoirs","author":"McKernan","year":"2012","journal-title":"Adv. Virol."},{"key":"10.1016\/j.antiviral.2015.06.017_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0001342","article-title":"Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever","volume":"5","author":"Mendenhall","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.antiviral.2015.06.017_b0200","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1473-3099(14)71047-3","article-title":"Dose regimen of favipiravir for Ebola virus disease","volume":"15","author":"Mentr\u00e9","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.06.017_b0205","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.017_b0210","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1128\/JVI.03114-13","article-title":"Inhibition of dengue and chikungunya virus infection by RIG-I-mediated type I IFN-independent stimulation of the innate antiviral response","volume":"88","author":"Olagnier","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.06.017_b0215","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.antiviral.2011.05.006","article-title":"Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus","volume":"91","author":"\u00d6lschl\u00e4ger","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.017_b0220","doi-asserted-by":"crossref","first-page":"e527","DOI":"10.1371\/journal.pone.0000527","article-title":"Human muscle satellite cells as targets of chikungunya virus infection","volume":"2","author":"Ozden","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2015.06.017_b0225","doi-asserted-by":"crossref","first-page":"21899","DOI":"10.1074\/jbc.M802444200","article-title":"Inhibition of chikungunya virus infection in cultured human muscle cells by furin inhibitors: impairment of the maturation of the E2 surface glycoprotein","volume":"283","author":"Ozden","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2015.06.017_b0230","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.coviro.2011.10.030","article-title":"Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action","volume":"1","author":"Paeshuyse","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2015.06.017_b0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003312","article-title":"Development of a highly protective combination monoclonal antibody therapy against chikungunya virus","volume":"9","author":"Pal","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2015.06.017_b0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002405","article-title":"Administration of E2 and NS1 siRNAs inhibit chikungunya virus replication in vitro and protects mice infected with the virus","volume":"7","author":"Parashar","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.antiviral.2015.06.017_b0245","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1473-3099(11)70065-2","article-title":"Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial","volume":"11","author":"Paton","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.06.017_b0250","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","article-title":"New hepatitis C therapies: the toolbox, strategies, and challenges","volume":"146","author":"Pawlotsky","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.06.017_b0255","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1126\/science.1132998","article-title":"RIG-I-mediated antiviral responses to single-stranded RNA bearing 5\u2032-phosphates","volume":"314","author":"Pichlmair","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2015.06.017_b0260","doi-asserted-by":"crossref","first-page":"e28923","DOI":"10.1371\/journal.pone.0028923","article-title":"Inhibitors of alphavirus entry and replication identified with a stable chikungunya replicon cell line and virus-based assays","volume":"6","author":"Pohjala","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2015.06.017_b0265","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.chembiol.2012.07.012","article-title":"The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2","volume":"19","author":"Polier","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.antiviral.2015.06.017_b0270","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1749-6632.1977.tb21977.x","article-title":"Antiviral action and selectivity of 6-azauridine","volume":"284","author":"Rada","year":"1977","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.antiviral.2015.06.017_b0275","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.antiviral.2013.12.010","article-title":"Chikungunya virus nsP3 & nsP4 interacts with HSP-90 to promote virus replication: HSP-90 inhibitors reduce CHIKV infection and inflammation in vivo","volume":"103","author":"Rathore","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.017_b0280","doi-asserted-by":"crossref","first-page":"10064","DOI":"10.1021\/jm301201z","article-title":"Flavaglines as potent anticancer and cytoprotective agents","volume":"55","author":"Ribeiro","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2015.06.017_b0285","unstructured":"Roques, P., Joubert, C., Delache, B., Calvo, J., Morin, J., Martinon, F., Lebon, P., Cherel, Y., Larcher, T., Aumont, G., de Lamballerie, X., Le Grand, R., 2007. Effet adverse d\u2019un traitement \u00e0 la chloroquine sur l\u2019infection \u00e0 Chikungunya dans le mod\u00e8le macaque\/ChikV OPY1. In: Colloque Chikungunya and Arbovirosis. La R\u00e9union."},{"issue":"5","key":"10.1016\/j.antiviral.2015.06.017_b9005","doi-asserted-by":"crossref","first-page":"e0126360","DOI":"10.1371\/journal.pone.0126360","article-title":"Acombination of doxycycline and ribavirin alleviated chikungunya infection","volume":"10","author":"Rothan","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2015.06.017_b0290","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1128\/AAC.00886-13","article-title":"Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome","volume":"57","author":"Safronetz","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.06.017_b0295","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.01.016","article-title":"Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment","volume":"104","author":"Scharton","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.017_b0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002423","article-title":"A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease","volume":"7","author":"Selvarajah","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.antiviral.2015.06.017_b0305","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11908-011-0180-1","article-title":"Chikungunya virus infection","volume":"13","author":"Simon","year":"2011","journal-title":"Curr. Infect. Dis. Rep."},{"key":"10.1016\/j.antiviral.2015.06.017_b0310","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","article-title":"Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model","volume":"104","author":"Smither","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.017_b0315","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.virol.2009.07.024","article-title":"Replication cycle of chikungunya: a re-emerging arbovirus","volume":"393","author":"Solignat","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2015.06.017_b0320","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.antiviral.2013.06.009","article-title":"Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy","volume":"99","author":"Thiberville","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.017_b0325","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/CEOR.S60710","article-title":"Respiratory syncytial virus: current and emerging treatment options","volume":"6","author":"Turner","year":"2014","journal-title":"Clin. Outcomes Res."},{"key":"10.1016\/j.antiviral.2015.06.017_b0330","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.4049\/jimmunol.1003139","article-title":"Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency","volume":"186","author":"Warter","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2015.06.017_b0335","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2015.04.016","article-title":"Chikungunya: evolutionary history and recent epidemic spread","volume":"120","author":"Weaver","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.017_b0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2014.11.001","article-title":"The green tea catechin, epigallocatechin gallate inhibits chikungunya virus infection","volume":"113","author":"Weber","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.06.017_b0345","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/jmv.23403","article-title":"Identification of prohibitin as a chikungunya virus receptor protein","volume":"84","author":"Wintachai","year":"2012","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2015.06.017_b0350","doi-asserted-by":"crossref","DOI":"10.1111\/1348-0421.12230","article-title":"Assessment of flavaglines as potential chikungunya virus entry inhibitors","author":"Wintachai","year":"2015","journal-title":"Microbiol. Immunol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215001485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215001485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T08:51:57Z","timestamp":1537519917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215001485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":71,"alternative-id":["S0166354215001485"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.06.017","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards antivirals against chikungunya virus","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}